Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Mar 31, 2017
Dec 31, 2016
Sep 30, 2016
Jun 30, 2016
Total Revenue
303,745
300,091
279,896
300,131
Cost of Revenue
50,006
64,147
50,738
51,617
Gross Profit
253,739
235,944
229,158
248,514
Operating Expenses
Research Development
145,003
175,242
160,831
167,039
Selling General and Administrative
120,019
142,958
118,758
109,577
Non Recurring
--
--
--
--
Others
8,925
7,365
9,654
544,704
Total Operating Expenses
273,947
325,565
289,243
821,320
Operating Income or Loss
(20,208)
(89,621)
(60,085)
(572,806)
Income from Continuing Operations
Total Other Income/Expenses Net
(4,751)
4,261
1,619
(1,552)
Earnings Before Interest And Taxes
(21,887)
(82,434)
(56,833)
(573,001)
Interest Expense
2,419
9,732
9,980
9,944
Income Before Tax
(24,306)
(92,166)
(66,813)
(582,945)
Income Tax Expense
(8,016)
(13,455)
(24,016)
(159,385)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(16,290)
(78,711)
(42,797)
(423,560)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(16,290)
(78,711)
(42,797)
(423,560)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(16,290)
(78,711)
(42,797)
(423,560)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information